Outcome measures in peripheral neuropathies: Requirements through statements

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 556-563

  Merkies, Ingemar S J ^a,b   Lauria, Giuseppe ^c   Faber, Catharina G ^b  

^a N   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

clinimetrics; MCID; outcome measures; peripheral neuropathies; Rasch analysis

Indexed keywords

IMMUNOGLOBULIN; RASAGILINE;

CLINICAL ASSESSMENT TOOL; FATIGUE; HUMAN; MEDICAL EDUCATION; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PHYSICIAN; REVIEW; SHORT FORM 36; TENDON REFLEX;

BIOMEDICAL RESEARCH; CONSENSUS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84866341132     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357f30f     Document Type: Review

References (42)

1. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. Br Med J 2003; 327:1459-1461. (Pubitemid 38045824)
2. Merkies ISJ. Evaluation of scales and measurement instruments in immunemediated polyneuropathies. Thesis. Rotterdam: Erasmus Medical Center; 2001.
3. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199-207.
4. Aaronson NK. Quality of life: what is it? How should it be measured? Oncology (Williston Park) 1988; 2:69-76; 64.
5. van Nes SI, Faber CG, Merkies IS. Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst 2008; 13:136-147. (Pubitemid 351871606)
6. Streiner DL, Norman GR. Health measurement scales. A practical guide to. their development and use. 2nd ed. New York: Oxford University Press; 1998
7. Feinstein AR. Clinimetrics. New Haven and London: Yale University Press; 1987.
8. Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995; 22:1191-1192.
9. Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum 2007; 57:1358-1362. (Pubitemid 350308830)
10. Rasch G. Probabilistic models for some intelligence and attainment tests. Chicago: University of Chicago Press; 1960.
11. Picavet HSJ. Public health questions on physical disabilities and musculoskeletal conditions: studies using health surveys. Thesis. Wageningen: Wageningen University; 2001.
12. The International Classification of Functioning, Disability and Health (ICF). Geneva: WHO; 2001.
13. Lunn MP, Leger JM, Merkies IS, et al. 151st ENMC international workshop: Inflammatory Neuropathy Consortium 13th-15th April 2007, Schiphol, The Netherlands. Neuromuscul Disord 2008; 18:85-89. (Pubitemid 351175653)
14. Merkies IS, Lauria G. 131st ENMC International workshop: selection of outcome measures for peripheral neuropathy clinical trials, 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 2006; 16:149-156. (Pubitemid 43190749)
15. Stucki G, Daltroy L, Katz JN, et al. Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 1996; 49:711-717. (Pubitemid 26280720)
16. DeVellis RF. Classical test theory. Med Care 2006; 44 (11 Suppl 3):S50-S59.
17. Svensson E. Guidelines to statistical evaluation of data from rating scales and questionnaires. J Rehabil Med 2001; 33:47-48. (Pubitemid 32401161)
18. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991; 41:799-807.
19. Merkies IS, Hughes RA, Donofrio P, et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 2010; 15:208-215.
20. Merkies IS, Schmitz PI, van der Meche FG, et al. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2003; 74:99-104. (Pubitemid 36069044)
21. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011; 76:337-345.
22. Wright BD. Local dependency, correlations and principal components. Rasch Meas Transact 1996; 10:509-511.
23. Vanhoutte EK, Faber CG, Merkies IS. MRC sum-score in the ICU: good reliability does not necessarily reflect 'true reliability'. Muscle Nerve 2012; 45:767-768.
24. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 1991; 14:1103-1109.
25. Hermans G, Clerckx B, Vanhullebusch T, et al. Interobserver agreement of medical research council sum-score and handgrip strength in the intensive care unit. Muscle Nerve 2012; 45:18-25.
26. Vanhoutte EK, Faber CG, van Nes SI, et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012; 135:1639-1649.
27. Dorans NJ, Holland PW. DIF detection and description: Mantel-Haenszel and standardisation. In: Holland PW, Wainer H, editors. Differential item functioning. Hillsdale, NJ: Lawrence Erlbaum Associates; 1993. pp. 36-66.
28. Ware JE Jr, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51:1167-1170. (Pubitemid 28527172)
29. Ware Jr JE, Kosinski M, Gandek B. SF-361 Health Survey. Manual and interpretation guide. Lincoln, RI: QualityMetric Inc; 2000.
30. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195-201. (Pubitemid 32738144)
31. Vanhoutte EK, Faber CG, Merkies IS. [Statistical significance or clinical relevance?]. Ned Tijdschr Geneeskd 2010; 154:A2516.
32. Sterne JA, Davey Smith G. Sifting the evidence: what's wrong with significance tests? Br Med J 2001; 322:226-231. (Pubitemid 32116172)
33. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268-1278.
34. Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inform J 2003; 37:23-31. (Pubitemid 37305150)
35. Copay AG, Subach BR, Glassman SD, et al. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007; 7:541-546. (Pubitemid 47471437)
36. Jaeschke R, Singer J, Guyatt GH. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
37. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002; 14:109-114. (Pubitemid 34185291)
38. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebocontrolled trial. Lancet Neurol 2008; 7:136-144.
39. Merkies IS, van Nes SI, Hanna K, et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 2010; 81:1194-1199.
40. Merkies IS, Hughes RA. The measurement of disease. J Neurol Neurosurg Psychiatry 2010; 81:943.
41. Hays RD, Morales LS, Reise SP. Item response theory and health outcomes measurement in the 21st century. Med Care 2000; 38 (9 Suppl):II28-42.
42. Andrich D. Controversy and the Rasch model: a characteristic of incompatible paradigms? Med Care 2004; 42 (1 Suppl):I7-16.